definitely it is a negative result, you can only go by what was published and not statistical for inflammatory, and barely statistical for non inflammatory. so its not going to become a drug at all. what bothers me is this will affect their pipeline potential especially their new product antibacterial. Given the poor results here, doubtful they will ever get a working drug at all.
This is a dressed up Argonaut shell that has gone from 2cents IPO to as high on 27 cents, without even a phase 2 positive result. Pure pump and dump!
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-69
-
- There are more pages in this discussion • 334 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |